Trial in Progress: OMNIA-2, Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma
read morePress Releases
Anaveon Presents Trial in Progress Data for OMNIA-1 at the American Society of Clinical Oncology 2023 Annual Meeting
OMNIA-1, a Phase I/II study of ANV419, an IL- 2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti-PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma
read moreAnaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for Cancer Research (AACR) 23rd Annual Meeting being held from Friday, April 14, 2023, to Wednesday, April 19, 2023, in Orlando, Florida.
read moreAnaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study – a Phase I/II study assessing the safety, tolerability and preliminary efficacy of ANV419 for the treatment of patients with relapsed / refractory multiple myeloma as monotherapy and in combination with daratumumab and hyaluronidase-fihj1, or with lenalidomide plus dexamethasone. ANV419 is a powerful, IL-2Rb selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2.
read moreAnaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
– OMNIA-1 is a Phase I/II study to determine the efficacy of ANV419 as monotherapy and in combination with anti-PD1 or anti-CTLA4 antibodies in advanced melanoma –
read moreAnaveon appoints Dr Eduard Gasal as Chief Medical Officer
Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO).
read moreAnaveon presents updated data from the Phase I/II study of ANV419 during the SITC Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA
read moreAnaveon announces upcoming poster presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA.
read moreAnaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
Anaveon, a clinical-stage immuno-oncology company, today announces updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022.
read more